NCT07172919 2026-04-09
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Amgen
Phase 2 Recruiting
Clinical Trials
15 trialsNCT05605496 2026-02-10
IMMUNONET
Centre Leon Berard
Phase 2 Active not recruiting
NCT07046650 2025-07-01
Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors
Fudan University
Phase 2 Recruiting
NCT05541822 2025-05-22
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Abion Inc
Phase 2 Recruiting
NCT06895928 2025-04-22
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT04716634 2025-03-25
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT06704828 2024-11-26
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT02057380 2024-11-20
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Astellas Pharma Inc
Phase 2 Completed
NCT03461952 2024-02-22
NIMBLe
Canadian Cancer Trials Group
Phase 2 Terminated
NCT02454972 2023-03-02
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
PharmaMar
Phase 2 Completed
NCT04169672 2023-03-02
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
Hutchmed
Phase 2 Completed
NCT04518137 2023-01-31
A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)
Antengene Corporation
Phase 2 Terminated
NCT05214976 2022-12-22
A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT05349409 2022-06-30
A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Unknown
NCT05254665 2022-02-24
A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Unknown